biomarker-based diagnostics | GenomeWeb

biomarker-based diagnostics

The guidance includes recommendations for extended RAS mutation testing to guide anti-EGFR therapy, as well as updated endorsements for analysis of mismatch repair status.

Single-cell RNA sequencing on thousands of tumor and surrounding cells from 19 melanoma samples revealed subsets of cells with apparent resistance potential.

Looking beyond PD-L1 expression, investigators from several clinical trials considered a range of potential biomarkers for immune checkpoint treatment response.

The company presented its findings last week at the 2016 Gastrointestinal Cancer Symposium and is preparing to launch the assay in the US later this year.

The test could provide an early diagnosis of breast cancer by examining a handful of miRNA, microRNA, and proteomic biomarkers from urine samples. 

This summer, BioNTech Diagnostics launched MammaTyper, a CE-IVD kit for breast cancer classification that measures the expression of four genes by RT-qPCR.

The kit targets several mRNA biomarkers and is the first in a series of salivary diagnostic kits the firm plans to develop for early-stage disease diagnostics.

NEW YORK (GenomeWeb News) – C2N Diagnostics today announced a research and supplier agreement with Cambridge Isotope Laboratories to provide C2N access to large quantities of highly enriched stable isotopes.

NEW YORK (GenomeWeb News) – Metabolomics firm Metabolon and Spain's IMDEA Food today said they are collaborating on projects to develop functional foods and diagnostic tools.

NEW YORK (GenomeWeb News) – Cancer Research UK's commercial arm, Cancer Research Technology (CRT), will partner with the biomarker validation firm Abcodia to develop blood tests for detecting early-stage cancers, CRUK said today.

Pages

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.